Home›Trial›NCT06925542
NCT06925542Phase 1RECRUITING

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

Study Summary

This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).

Conditions
SLE (Systemic Lupus)Lupus Erythematosus, SystemicLupus NephritisSystemic SclerosisInflammatory Myopathy, IdiopathicMyositisDiffuse Cutaneous Systemic Sclerosis
Interventions / Drugs
CTX112
View on ClinicalTrials.gov ↗
Sponsor
CRSP
CRISPR Therapeutics
Gene Editing
D47/100
Study Details
Enrollment80 participants
Primary Completion—
Lead SponsorCRISPR Therapeutics
Data Retrieved2026-04-11 04:10:52.767972+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 80 participants
Sponsor Catalyst Profile

CRISPR Therapeutics (CRSP) is the sponsoring company for this trial. BiotechSign currently grades this company D (47/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

CRSP Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.